CUG 105
Alternative Names: CUG-105Latest Information Update: 20 Apr 2022
Price :
$50 *
At a glance
- Originator Cugene
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 15 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bladder cancer; Solid tumours
Most Recent Events
- 20 Apr 2022 CUG 105 is available for licensing as of 20 Apr 2022. https://cugene.com/investors/
- 20 Apr 2022 Preclinical trials in Bladder cancer in USA (Parenteral), prior to April 2022 (Cugene pipeline, April 2022)
- 20 Apr 2022 Preclinical trials in Solid tumours in USA (Parenteral), prior to April 2022 (Cugene pipeline, April 2022)